588 related articles for article (PubMed ID: 16907718)
1. Azole antifungals as novel chemotherapeutic agents against murine tuberculosis.
Ahmad Z; Sharma S; Khuller GK
FEMS Microbiol Lett; 2006 Aug; 261(2):181-6. PubMed ID: 16907718
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapeutic evaluation of alginate nanoparticle-encapsulated azole antifungal and antitubercular drugs against murine tuberculosis.
Ahmad Z; Sharma S; Khuller GK
Nanomedicine; 2007 Sep; 3(3):239-43. PubMed ID: 17652032
[TBL] [Abstract][Full Text] [Related]
3. The potential of azole antifungals against latent/persistent tuberculosis.
Ahmad Z; Sharma S; Khuller GK
FEMS Microbiol Lett; 2006 May; 258(2):200-3. PubMed ID: 16640573
[TBL] [Abstract][Full Text] [Related]
4. Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles.
Ahmad Z; Pandey R; Sharma S; Khuller GK
Int J Antimicrob Agents; 2008 Feb; 31(2):142-6. PubMed ID: 18155883
[TBL] [Abstract][Full Text] [Related]
5. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model.
Pandey R; Khuller GK
J Antimicrob Chemother; 2004 Jul; 54(1):266-8. PubMed ID: 15128731
[TBL] [Abstract][Full Text] [Related]
7. In vitro and ex vivo antimycobacterial potential of azole drugs against Mycobacterium tuberculosis H37Rv.
Ahmad Z; Sharma S; Khuller GK
FEMS Microbiol Lett; 2005 Oct; 251(1):19-22. PubMed ID: 16143463
[TBL] [Abstract][Full Text] [Related]
8. [Studies on therapeutic efficacy of a new anti-tuberculous drug, benzoxazinorifamycin, against murine experimental mycobacterial infections: attempt at various regimens and protocols].
Tomioka H; Saito H
Kekkaku; 1994 Nov; 69(11):703-10. PubMed ID: 7837724
[TBL] [Abstract][Full Text] [Related]
9. Gatifloxacin in combination with rifampicin in a murine tuberculosis model.
Cynamon M; Sklaney MR; Shoen C
J Antimicrob Chemother; 2007 Aug; 60(2):429-32. PubMed ID: 17561504
[TBL] [Abstract][Full Text] [Related]
10. Trench warfare in a battle with TB.
Marshall E
Science; 2008 Jul; 321(5887):362-4. PubMed ID: 18635790
[No Abstract] [Full Text] [Related]
11. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis.
Sharma A; Sharma S; Khuller GK
J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364
[TBL] [Abstract][Full Text] [Related]
12. Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system.
Milano A; Pasca MR; Provvedi R; Lucarelli AP; Manina G; Ribeiro AL; Manganelli R; Riccardi G
Tuberculosis (Edinb); 2009 Jan; 89(1):84-90. PubMed ID: 18851927
[TBL] [Abstract][Full Text] [Related]
13. Activity of diclofenac used alone and in combination with streptomycin against Mycobacterium tuberculosis in mice.
Dutta NK; Mazumdar K; Dastidar SG; Park JH
Int J Antimicrob Agents; 2007 Oct; 30(4):336-40. PubMed ID: 17644321
[TBL] [Abstract][Full Text] [Related]
14. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
Pandey R; Sharma S; Khuller GK
Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
[TBL] [Abstract][Full Text] [Related]
15. Antimycobacterial activity of econazole against multidrug-resistant strains of Mycobacterium tuberculosis.
Ahmad Z; Sharma S; Khuller GK; Singh P; Faujdar J; Katoch VM
Int J Antimicrob Agents; 2006 Dec; 28(6):543-4. PubMed ID: 17101262
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles.
Dutt M; Khuller GK
J Antimicrob Chemother; 2001 Jun; 47(6):829-35. PubMed ID: 11389115
[TBL] [Abstract][Full Text] [Related]
17. Role of human neutrophil peptide-1 as a possible adjunct to antituberculosis chemotherapy.
Kalita A; Verma I; Khuller GK
J Infect Dis; 2004 Oct; 190(8):1476-80. PubMed ID: 15378441
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of moxifloxacin & econazole against multidrug resistant (MDR) Mycobacterium tuberculosis in murine model.
Gupta UD; Vemuri N; Gupta P; Kumar V; Tanushree P; Khuller GK
Indian J Med Res; 2015 Sep; 142(3):323-9. PubMed ID: 26458349
[TBL] [Abstract][Full Text] [Related]
19. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes.
Labana S; Pandey R; Sharma S; Khuller GK
Int J Antimicrob Agents; 2002 Oct; 20(4):301-4. PubMed ID: 12385689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]